CLDI.AMEXCalidi Biotherapeutics, INC
10-Q: Calidi Biotherapeutics Reports First Quarter 2024 Results Amidst Financial Uncertainty
Sentiment:
Quarterly Report
Calidi Biotherapeutics reports a net loss of $7.2 million for the first quarter of 2024, alongside concerns about its ability to continue as a going concern.
Capital raiseThe company is actively seeking additional capital through public or private equity or debt financings.The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., for up to $25.0 million of its shares of Common Stock.The company closed on a public offering of its securities on April 18, 2024, for gross proceeds of approximately $6.1 million.
Worse than expectedThe company's net loss increased compared to the same period last year.The company's general and administrative expenses increased significantly.The company has expressed substantial doubt about its ability to continue as a going concern.
Summary
- Calidi Biotherapeutics reported a net loss of $7.2 million for the three months ended March 31, 2024, compared to a net loss of $6.5 million for the same period in 2023.
- The company's research and development expenses were $2.7 million, a slight increase from $2.6 million in the prior year.
- General and administrative expenses increased significantly to $4.0 million from $2.8 million year-over-year.
- The company's cash balance stood at $1.2 million as of March 31, 2024, with an accumulated deficit of $106.8 million.
- Management has expressed substantial doubt about the company's ability to continue as a going concern within the next 12 months, citing the need for additional funding.
- The company is actively seeking additional capital through public or private equity or debt financings.
- Calidi is developing several product candidates, including CLD-101 for high-grade glioma and CLD-201 for advanced solid tumors, with clinical trials expected to commence in the near future.
Sentiment
Score: 3
Explanation: The document presents a concerning financial situation with a significant net loss, high operating expenses, and substantial doubt about the company's ability to continue as a going concern. While there is progress in clinical trials, the financial risks overshadow the potential positives.
Positives
- The company is progressing with clinical trials for CLD-101 and CLD-201, with trials expected to begin in the second half of 2024.
- Calidi has a pipeline of off-the-shelf allogeneic cell product candidates designed to protect oncolytic viruses from inactivation and target tumor sites.
- The company is developing engineered oncolytic vaccinia virus constructs and allogeneic cell-based platforms with improved systemic anti-tumor immunity.
Negatives
- The company reported a net loss of $7.2 million for the first quarter of 2024.
- General and administrative expenses increased significantly to $4.0 million.
- The company has a substantial accumulated deficit of $106.8 million.
- There is substantial doubt about the company's ability to continue as a going concern due to insufficient cash reserves.
- The company is dependent on raising additional capital to fund its operations.
Risks
- The company's ability to continue as a going concern is uncertain due to insufficient cash reserves.
- The company is dependent on raising additional capital, which may not be available on favorable terms or at all.
- The company's product candidates are subject to long development cycles and may not receive regulatory approval.
- The company faces competition from other biotechnology companies.
- Changes in economic conditions, including rising interest rates and supply chain disruptions, may affect the company's operations.
- The company's stock price may be adversely affected by the sale of a substantial number of shares by selling securityholders.
Future Outlook
The company expects to continue to incur significant operating losses and will need to raise substantial additional funding to support its continuing operations and pursue its growth strategy. The company anticipates commencing a Phase 1 clinical trial for SNV1 during the second half of 2024 and a Phase 1b clinical trial for NNV1 during the third quarter of 2024.
Management Comments
- Management estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of the financial statements.
- Management plans to raise additional capital through public or private equity or debt financings to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the financial statements.
Industry Context
Calidi Biotherapeutics operates in the competitive immuno-oncology sector, focusing on developing novel cell-based platforms for oncolytic virotherapies. The company's approach of using stem cells to deliver and potentiate oncolytic viruses is a growing area of interest in cancer treatment. The company's financial challenges highlight the capital-intensive nature of biotechnology development and the risks associated with early-stage clinical programs.
Comparison to Industry Standards
- Calidi's financial situation, with a significant accumulated deficit and concerns about going concern, is not uncommon for early-stage biotech companies that are pre-revenue and heavily reliant on external funding.
- Compared to other companies in the immuno-oncology space, Calidi's research and development expenses are relatively low, reflecting its current stage of development and focus on preclinical and early clinical trials.
- The increase in general and administrative expenses is typical for companies transitioning to public status and scaling up operations.
- The company's reliance on related-party financing is a common practice for early-stage companies but also introduces potential conflicts of interest and governance concerns.
- The company's clinical trial plans for CLD-101 and CLD-201 are in line with industry standards for developing novel cancer therapies, but the timelines and costs are subject to significant uncertainty.
Legal Proceedings
- The company is involved in a legal dispute with former physicians regarding stock options, which was settled on February 5, 2024.
- The company is involved in a legal dispute with its former chief accounting officer and interim chief financial officer, Tony Kalajian, who filed a complaint on November 15, 2023, and another on May 1, 2024.
Related Party Transactions
- The company has funded its operations through investments from related parties, including AJC Capital and certain directors.
- The company has related party term notes payable, accounts payable, accrued expenses, and loan payables.
- The company has a lease guaranty with a related party.
Stakeholder Impact
- Shareholders face significant dilution risk due to potential future equity offerings and the conversion of outstanding securities.
- Employees may be affected by the company's financial instability and potential restructuring.
- Customers and suppliers may be impacted by the company's ability to continue operations and fulfill its obligations.
- Creditors face the risk of non-payment due to the company's financial challenges.
Next Steps
- The company plans to commence a Phase 1b clinical trial for NNV1 in collaboration with Northwestern University during the third quarter of 2024.
- The company anticipates commencing a Phase 1 clinical trial for SNV1 during the second half of 2024.
- The company will hold a special meeting on June 6, 2024, to seek stockholder approval for a reverse stock split.
Key Dates
| Date | Description |
|---|---|
| 2021-01-31 | Date of 2021 Term Note agreement with a related party investor and director. |
| 2021-06-07 | Date of License Agreement with Northwestern University. |
| 2021-07-22 | Date of Exclusive License Agreement with City of Hope and the University of Chicago. |
| 2022-02-01 | Appointment of George K. Ng as President and Chief Operating Officer. |
| 2022-03-14 | Date of terminated physician agreement. |
| 2022-04-01 | Date of StemVac office lease commencement. |
| 2022-04-01 | Date of Advisory Agreement with Scott Leftwich. |
| 2022-05-31 | Date of 2019 Plan Administrator. |
| 2022-10-10 | Date of San Diego Office Lease Agreement. |
| 2022-10-27 | Date of CIRM grant approval. |
| 2022-11-30 | Date of 2022 Term Note issuance. |
| 2022-12-06 | Date of mediation with physicians. |
| 2023-01-18 | Date of stock option repricing. |
| 2023-03-01 | Commencement date of San Diego Lease. |
| 2023-06-23 | Date of Separation and Release Agreement with George Ng. |
| 2023-08-28 | Date of 2023 Employee Stock Purchase Plan approval. |
| 2023-08-31 | Termination of Advisory Agreement with Scott Leftwich. |
| 2023-09-11 | Date of Mr. Kalajian's separation. |
| 2023-09-12 | Date of FLAG Merger consummation. |
| 2023-09-19 | Date of Second Amended and Restated Certificate of Incorporation. |
| 2023-11-15 | Date of Tony Kalajian's complaint filing. |
| 2023-12-10 | Date of Standby Equity Purchase Agreement (SEPA) with Yorkville. |
| 2024-01-19 | Date of 2024 Bridge Loan issuance. |
| 2024-01-26 | Date of 2024 Convertible Note Loan agreement. |
| 2024-02-05 | Date of settlement agreement with physicians. |
| 2024-02-21 | Date of issuance of warrants to purchase Restricted Shares. |
| 2024-03-08 | Date of Settlement Agreement and Convertible Promissory Note Purchase Agreement. |
| 2024-03-25 | Date of consulting agreement. |
| 2024-04-12 | Date of extension of 2022 and 2023 Term Notes. |
| 2024-04-14 | Date of amendment to $1.5 million convertible note agreement. |
| 2024-04-18 | Date of closing of public offering. |
| 2024-04-19 | Date of full payment of $1.5 million convertible note. |
| 2024-04-26 | Record date for special meeting. |
| 2024-04-29 | Date of preliminary proxy statement filing. |
| 2024-05-01 | Date of Mr. Kalajian's complaint filing. |
| 2024-05-10 | Date of outstanding shares of common stock. |
| 2024-06-06 | Date of special meeting. |
Keywords
Biotherapeutics, Oncolytic Virus, Immunotherapy, Clinical Trials, Stem Cell, Cancer Therapy, Biotechnology, Financial Results, Going Concern, Capital Raise
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.